使用人工智能在家中测量帕金森病的严重程度
Md Saiful Islam1,2, Wasifur Rahman3, Abdelrahman Abdelkader3
1Department of Computer Science, University of Rochester, 250 Hutchinson Road, Rochester, NY, 14620, USA. mislam6@ur.rochester.edu.
NPJ digital medicine
|August 23, 2023
概括
一个人工智能系统通过使用手指敲击测试远程评估帕金森病 (PD) 运动功能. 这种人工智能工具显示出客观,远程评估的潜力,改善了运动障碍患者获得护理的机会.
科学领域:
- 神经学 神经学
- 人工智能的人工智能
- 生物医学工程 生物医学工程
背景情况:
- 帕金森病 (PD) 的诊断和监测依赖于主观的临床评估.
- 在PD中远程评估运动功能是具有挑战性的,因为获得专业护理的机会有限.
研究的目的:
- 开发和验证人工智能系统,以客观地远程评估帕金森病患者的运动性能.
- 通过使用运动障碍学会统一帕金森病评级表 (MDS-UPDRS) 与专家神经病学家评级相关联人工智能衍生的客观措施.
主要方法:
- 250名患有PD的参与者通过网络摄像头远程执行了一项指尖敲击任务.
- 专家神经病学家使用MDS-UPDRS (0-4级) 评价运动症状严重程度,评级者之间的可靠性很好 (ICC=0.88).
- 计算机算法提取了客观的运动性能指标,并在这些数据上训练了一种机器学习模型.
主要成果:
- 人工智能衍生的客观指标与神经病学家评级有很强的相关性.
- 机器学习模型实现了0.58的平均绝对误差 (MAE),表现优于认证评级者 (MAE=0.83),但表现略低于专家神经科医生 (MAE=0.53).
结论:
- 开发的AI系统为帕金森病的远程客观运动评估提供了一种可行的方法.
- 这项技术有可能改善PD和其他运动障碍患者获得神经治疗的机会,特别是在服务不足的地区.
相关概念视频
Parkinson's Disease: Treatment
297
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
297
Parkinson's Disease: Overview
596
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
596


